Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psoriasis plaque test of LAS41004 retinoid + steroid ointment concentrations
2011-001384-45Phase 2Completed
- Sponsor
- Almirall
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of LAS41004 IMP5, tazarotene and betamethasone dipropionate in plaque psoriasis (3 arms), sponsored by Almirall. Primary endpoint: Area under the curve of skin thickness. Started Jun 2011; status: completed.
02
Drugs
LAS41004 IMP5tazarotenebetamethasone dipropionate
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2011-001384-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001384-45.